Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- SHLM +5.5%, TGT +4%, STX +2.5%, (Seagate Tech expects to report Q2 revenue of approximately $2.9 billion vs $2.74 bln consensus), CFMS +2%, SFM +0.9%, (Sprouts Farmers Market expects FY17 EPS to be slightly above previous guidance; Sees Q4 SSS growth of +4.6%), LMNR +0.8%, DLR +0.7%
Other news:
- PSTI +10.2% (FDA has cleared the Company's Expanded Access Program (EAP) for the use of its PLX-PAD cell treatment in patients with Critical Limb Ischemia)
- BPT +9.8% (increases Q4 dividend payment to $1.2301519/unit from $0.6758286/unit)
- ATUS +8.9% (ticking higher; Altice N.V. approved plans for the separation of Altice USA from Altice NV )
- ILMN +8.8% (Illumina and Thermo Fisher Scientific sign commercial agreement that enables Illumina to sell Ion AmpliSeq technology; Illumina also announced the launch of the iSeq 100 Sequencing System)
- AXON +8.7% (announces a correction to the data related to the Company's investigational drug nelotanserin previously reported in its January 8, 2018 press release), ADMS +3.9% (announced full commercial launch of GOCOVRI extended release capsules for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy)
- SNOA +2.6% (receives three new United Arab Emirates regulatory approvals)
- BLDP +1.7% (Ballard Power will discuss strategic direction and recent progress within the 'rapidly expanding' fuel cell and clean energy area at Needham conference on Jan 17)
- FHN +1.7% (light volume; details Tax Cuts and Jobs Act impact - estimates reduction to fourth quarter earnings of approximately $95 million)
- NETE +1.3% (files for 1,079,136 share common stock offering by Esousa Holdings)
- INCY +1.3% (higher on light volume following JPM presentation)
- PODD +1.1% (announces strategic alliance with Ascensia Diabetes Care by signing commercial agreement)
Analyst comments:
- AAL +2.1% (upgraded to Buy from Underperform at BofA/Merrill)
- KKR +2% (added to Conviction Buy List at Goldman)
- TROW +1.6% (upgraded to Neutral from Sell at UBS)
- CCL +1.1% (upgraded to Outperform from Neutral at Credit Suisse)
- PYPL +0.9% (upgraded to Outperform from Market Perform at Cowen)